Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin)

American Journal of Pathology

Volumn 149, Issue 1, 1996, Pages 129-142

  Niehans, Gloria A ^b   Cherwitz, David L ^b   Staley, Nancy A ^b   Knapp, Dennis J ^b   Dalmasso, Agustin P ^a  

^a VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; INHIBITOR PROTEIN; MEMBRANE COFACTOR PROTEIN;

ARTICLE; BREAST CARCINOMA; CARCINOMA; COLON CARCINOMA; COMPLEMENT DEPOSITION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; BREAST; BREAST NEOPLASMS; CARCINOMA; COLON; COLONIC NEOPLASMS; COMPLEMENT C3; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; LUNG; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS;

EID: 0029900739     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Dalmasso AP: Complement in the pathophysiology and diagnosis of human diseases. Crit Rev Clin Lab Sci 1986, 24:123-183
2. Morgan BP: Cellular responses to the membrane attack complex. Complement in Health and Disease, ed 2. Edited by K Whaley, M Loos, JM Weiler. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1993, pp 325-351
3. Morgan BP, Meri S: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994, 15:369-396
4. Lublin DM, Atkinson JP: Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989, 7:35-58
5. Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160:1558-1578
6. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V: Identification of the complement decayaccelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987, 165:848-864
7. Zalman LS, Wood LM, Müller-Eberhard HJ: Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 1986, 83:6975-6979
8. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM: Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986, 136:1772-1776
9. Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M, Yano S: Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J Biochem 1989, 106:555-557
10. Davies A, Lachmann PJ: Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res 1993, 12:258-275
11. Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991, 65: 532-537
12. Rosse WF: Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 1990, 75: 1595-1601
13. McNearney T, Ballard L, Seya T, Atkinson JP: Membrane cofactor protein of complement is present on human fibroblast, epithelial and endothelial cells. J Clin Invest 1989, 84:538-545
14. Liszewski MK, Post TW, Atkinson JP: Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991, 9:431-455
15. Niculescu F, Rus HG, Retegan M, Vlaicu R: Persistent complement activation on tumor cells in breast cancer. Am J Pathol 1992, 140:1039-1043
16. Cheung N-KV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME: Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 1988, 81: 1122-1128
17. Seya T, Hara T, Matsumoto M, Sugita Y, Akedo H: Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med 1990, 172:1673-1680
18. Gee AP, Boyle MDP: Purging tumor cells from bone marrow by use of antibody and complement: a critical appraisal. J Natl Cancer Inst 1988, 80:154-159
19. Falk RJ, Dalmasso AP, Kim Y, Tsai CH, Scheinman JI, Gewurz H, Michael AF: Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983, 72:560-573
20. Sternberger LA: Immunocytochemistry, ed 2. New York, John Wiley and Sons, 1979
21. Seya T, Turner JR, Atkinson JP: Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986, 163:837-855
22. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF: Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982, 129:184-189
23. Rollins SA, Sims PJ: The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990, 144:3478-3483
24. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990, 71:1-9
25. Ollert MW, Frade R, Fiandino A, Panneerselvam M, Petrella EC, Barel M, Pangburn MK, Bredehorst R, Vogel C-W: C3-cleaving membrane proteinase: a new complement regulatory protein of human melanoma cells. J Immunol 1990, 144:3862-3867
26. Nakano Y, Sugita Y, Ishikawa Y, Choi N-H, Tobe T, Tomita M: Isolation of two forms of decay-accelerating factor (DAF) from human urine. Biochim Biophys Acta 1991, 1074:326-330
27. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H: CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989, 170:637-654
28. Bjorge L, Jensen TS, Vedeler CA, Ulvestad E, Kristoffersen EK, Matre R: Soluble CD59 in pregnancy and infancy. Immunol Lett 1993, 36:233-234
29. Rooney IA, Morgan BP: Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 1992, 76:541-547
30. Bjorge L, Vedeler CA, Ulvestad E, Matre R: Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 1994, 24:1597-1603
31. Kumar S, Vinci JM, Pytel BA, Baglioni C: Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993, 53:348-353
32. Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M: Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 1996, 74:33-42
33. Terachi T, Stanescu G, Pontes JE, Medof ME, Caulfield MJ: Coexistence of autologous antibodies and decayaccelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res 1991, 51:2521-2523
34. Sayama K, Shiraishi S, Miki Y: Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms. Br J Dermatol 1992, 127:1-4
35. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M, Imai Y: Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994, 73: 2808-2817
36. Cho S-W, Oglesby TJ, Hsi B-L, Adams EM, Atkinson JP: Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay. Clin Exp Immunol 1991, 83:257-261
37. Sakuma T, Kodama K, Hara T, Eshita Y, Shibata N, Matsumoto M, Seya T, Mori Y: Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma. Jpn J Cancer Res 1993, 84:753-759
38. Martin DE, Chiu FJ, Gigli I, Müller-Eberhard HJ: Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition. J Clin Invest 1987, 80:226-233
39. Bara S, Lint TF: The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J Immunol 1987, 138:1303-1309
40. Ramos OF, Nilsson B, Nilsson K, Eggertsen G, Yefenof E, Klein E: Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments. Cell Immunol 1989, 119:459-469
41. Perlmann H, Perlmann P, Schreiber RD, Müller-Eberhard HJ: Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors: enhancement of antibody-mediated cellular cytotoxicity. J Exp Med 1981, 153:1592-1603
42. Loveland BE, Szokolai K, Johnstone RW, McKenzie IFC: Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. Transplant Proc 1994, 26:1070-1071
43. Hsu S-M, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580
44. Ootaka T, Suzuki M, Sudo K, Sato H, Seino J, Saito T, Yoshinaga K: Histologic localization of terminal complement complexes in renal diseases: an immunohistochemical study. Am J Clin Pathol 1989, 91:144-151
45. Mabry M, Speak JA, Griffin JD, Stahel RA, Bernal SD: Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest 1985, 75:1690-1695
46. Irie K, Irie RF, Morton DL: Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science 1974, 186:454-456